NCT07187856 - Phase 2 Randomized Study of PG-102 vs Placebo and Semaglutide in Type 2 Diabetes Mellitus | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 31, 2026

Primary Completion Date

September 30, 2026

Study Completion Date

December 31, 2026

Conditions

Type 2 Diabetes Mellitus (T2DM)

Interventions

DRUG

PG-102

PG-102 is administered subcutaneously once weekly with a titration regimen.

DRUG

Placebo

Placebo is administered subcutaneously once weekly.

DRUG

Semaglutide

Open-label semaglutide is administered subcutaneously once weekly with titration regimen.

Trial Locations (1)

Emeritus Research, Camberwell

All Listed Sponsors

lead

ProGen. Co., Ltd.

OTHER